South Rampart Pharma: Funding, Investors & Team (Sep 2026)
South Rampart Pharma, Inc. is a biotech company in the clinical stage that focuses on developing a safe and efficient method of pain relief. Its main product, SRP-001, is a unique analgesic that targets pain signaling pathways in the midbrain's periaqueductal grey region. Unlike opioids, SRP-001 is non-addictive and does not pose a risk of abuse. Additionally, it does not have the liver toxicity associated with acetaminophen. In comparison to acetaminophen, SRP-001 offers similar pain relief properties without the risk of liver damage or kidney toxicity associated with NSAIDs. Early results from Phase 1 trials show that SRP-001 is safe, well-tolerated, and has promising pharmacokinetics. It has the potential to be a safer and more effective alternative to current pain medications.
South Rampart Pharma has raised $8.0M across 2 funding rounds on record, the most recent a Series A of $8.0M announced in May 2025.
That round is in line with the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
South Rampart Pharma Company Profile and Key Stats
Latest funding round on record: May 2025.
South Rampart Pharma Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
South Rampart Pharma announced an undisclosed round in Sep 2023; the amount was not disclosed.
1.7 years later, a Series A of $8.0M was announced in May 2025.
South Rampart Pharma Founders and Leadership Team
Contact details for the South Rampart Pharma team: 1 of 1 has an email address on file.
Start 14-day free trial →South Rampart Pharma Funding Compared to Other Biotechnology Startups
South Rampart Pharma's latest round of $8.0M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like South Rampart Pharma in Biotechnology and New Orleans
Companies Similar to South Rampart Pharma
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
South Rampart Pharma Funding FAQs
What does South Rampart Pharma do?
South Rampart Pharma, Inc. is a biotech company in the clinical stage that focuses on developing a safe and efficient method of pain relief. Its main product, SRP-001, is a unique analgesic that targets pain signaling pathways in the midbrain's periaqueductal grey region. Unlike opioids, SRP-001 is non-addictive and does not pose a risk of abuse. Additionally, it does not have the liver toxicity associated with acetaminophen. In comparison to acetaminophen, SRP-001 offers similar pain relief properties without the risk of liver damage or kidney toxicity associated with NSAIDs. Early results from Phase 1 trials show that SRP-001 is safe, well-tolerated, and has promising pharmacokinetics. It has the potential to be a safer and more effective alternative to current pain medications.
How much funding has South Rampart Pharma raised?
South Rampart Pharma has raised $8.0M across 2 rounds on record. The most recent is a Series A of $8.0M announced in May 2025.
When did South Rampart Pharma last raise funding?
South Rampart Pharma's most recent funding round on record is a Series A of $8.0M, announced in May 2025.
Who founded South Rampart Pharma?
FundedIQ lists Hernan Bazan (Founder) at South Rampart Pharma.
Where is South Rampart Pharma headquartered?
South Rampart Pharma is based in New Orleans, Louisiana, United States.
How many employees does South Rampart Pharma have?
South Rampart Pharma is in the 1-10 employee band.
How does South Rampart Pharma's funding compare to other Biotechnology startups?
South Rampart Pharma's latest round of $8.0M is in line with the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's South Rampart Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for South Rampart Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.